CLAIMS

1. Use of AIM, an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment in the manufacture of a medicament for treating or preventing a neurodegenerative disease, wherein the medicament is to be delivered into the brain.

2. The use according to claim 1, wherein the nucleic acid encoding AIM or AIM fragment is incorporated in a viral vector.

3. The use according to claim 2, wherein the viral vector is a viral vector selected from the group consisting of adeno-associated virus, adenovirus, lentivirus, and Sendai virus.

4. The use according to claim 2, wherein the viral vector is an adeno-associated virus.

5. The use according to claim 4, wherein the adeno-associated virus is AAV serotype 5 (AAV5) or AAV serotype 9 (AAV9).

6. The use according to any one of claims 1 to 5, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia, multiple system atrophy, Pick disease, corticobasal degeneration, progressive supranuclear paralysis, amyotrophic lateral sclerosis, spinobulbar muscular atrophy, spinal progressive muscular atrophy, Huntington’s disease, spinocerebella degeneration, hippocampus sclerosis, progressive myoclonus epilepsy, and dentatorubral-pallidoluysian atrophy.